Infect Chemother.  2017 Dec;49(4):297-300. 10.3947/ic.2017.49.4.297.

A Case of Community-Acquired Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii in Korea

• Son YW
• Jung IY
• Ahn MY
• Jeon YD
• Ann HW
• Ahn JY
• Ku NS
• Han SH
• Choi JY
• Song YG
• Kim JM

• KMID: 2399199
• DOI: http://doi.org/10.3947/ic.2017.49.4.297

Abstract

Acinetobacter baumannii is an aerobic Gram-negative coccobacillus that causes nosocomial pneumonia in patients on mechanical ventilation or previously treated with broad-spectrum antibiotics. Nevertheless, community-acquired pneumonia (CAP) caused by A. baumannii, especially multi-drug resistant (MDR) strains, is rare. We experienced the first case of CAP caused by MDR A. baumannii in Korea in a 78-year-old man. This case shows that MDR A. baumannii can cause CAP in Korea.

Keyword

Acinetobacter baumannii; Community-acquired pneumonia; Multi-drug-resistance

MeSH Terms

Acinetobacter baumannii*
Acinetobacter*
Aged
Anti-Bacterial Agents
Humans
Korea*
Pneumonia*
Respiration, Artificial
Anti-Bacterial Agents

Figure

• 

  Figure 1 Chest radiography. (A) The chest radiograph on admission showed lobar pneumonia in the right upper and middle lobes. (B) On the 48th day after admission, the chest radiograph showed improvement in the consolidations of the right and middle lobes.

• 

  Figure 2 Chest computed tomography (CT). (A) On admission, CT showed lobar pneumonia in the right upper and middle lobes with a parapneumonic effusion. (B) At the 48th day after admission, CT showed improvement in the consolidations of the right upper and middle lobes.

Reference

1. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006; 42:692–699.

2. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 2009; 73:355–363.

3. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest. 2006; 129:102–109.

4. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011; 55:4943–4960.

5. Kang SJ, Kang CI, Park SY, Ha YE, Joo EJ, Chung DR, Peck KR, Lee NY, Song JH. Epidemiology and clinical features of community-onset Acinetobacter baumannii infections. Infect control Hosp Epidemilo. 2012; 33:1053–1055.

6. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. Community-acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis. 2007; 26:857–868.

7. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis. 2001; 7:319–322.

8. Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y. KONSAR Group. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J. 2011; 52:793–802.

9. Han SH, Na DJ, Yoo YW, Kim DG, Moon YR, Moon KM, Lee YD, Cho YS, Han MS, Yoon HJ. A case of probable community acquired Acinetobacter baumannii pneumonia. Tuberc Respir Dis (Seoul). 2007; 63:273–277.

10. Kang CI, Song JH, Oh WS, Ko KS, Chung DR, Peck KR. Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. Eur J Clin Microbiol Infect Dis. 2008; 27:657–661.

11. Na JY, Min BW, Chung SH, Kim MY, Lee YJ, Park JT, Kim HS. A probable community-acquired pneumonia due to Acinetobacter baumannii infection presenting the positive pneumothorax test at autopsy. Korean J Leg Med. 2010; 34:125–128.

12. Lee Y, Yoon S, Lee HS, Kang BH, An J, Kim YJ, Hong SB, Choi SH. A case of severe community-acquired Acinetobacter baumannii pneumonia with bacteremia. Infect Chemother. 2012; 44:71–74.

13. Oh YJ, Song SH, Baik SH, Lee HH, Han IM, Oh DH. A case of fulminant community-acquired Acinetobacter baumannii pneumonia in Korea. Korean J Intern Med. 2013; 28:486–490.

14. Ong CW, Lye DC, Khoo KL, Chua GS, Yeoh SF, Leo YS, Tambyah PA, Chua AC. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. Respirology. 2009; 14:1200–1205.

15. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis. 1992; 14:83–91.

16. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012; 39:105–114.

17. Lee CS, Doi Y. Therapy of infections due to crbapenem-rsistant Gram-ngative pthogens. Infect Chemother. 2014; 46:149–164.

18. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013; 11:1333–1353.